Denmark has paid out one-third of Bavarian Nordic's Covid-19 vaccine support

The biotech firm’s development of a Covid-19 vaccine has so far triggered a DKK 240m (USD 33.9m) payment from the Danish state, which set aside a total of DKK 800m (USD 113m) in funding for a Danish vaccine candidate.

Bavarian Nordic’s scheduled initiation of a large phase III trial of its potential Covid-19 vaccine comes as a direct result of the Danish government’s financial support for the development program.

At the end of March, Bavarian Nordic had received a total DKK 240m (USD 33.9m) from the funding deal struck with the Danish Ministry of Health, which included an upfront payment of DKK 80m (USD 11.3m) when the agreement was made, with the DKK 160m (USD 22.6m) remainder coming in as milestone payments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs